A metabonomic analysis of organ specific response to USPIO administration

Biomaterials

Volumn 32, Issue 27, 2011, Pages 6558-6569

  Feng, Jianghua ^a,b   Liu, Huili ^b   Bhakoo, Kishore K ^c   Lu, Lehui ^d   Chen, Zhong ^a  

^a XIAMEN UNIVERSITY   (China)

^b Wuhan National Laboratory for Optoelectronics   (China)

^c AGENCY FOR SCIENCE   (Singapore)

^d CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

Author keywords

1H NMR spectroscopy; Biological effect; Correlation analysis; HR MAS; Metabonomics; USPIO

Indexed keywords

BIOLOGICAL EFFECTS; CORRELATION ANALYSIS; H NMR SPECTROSCOPY; HR-MAS; METABONOMICS; USPIO;

AMINO ACIDS; BIOLOGICAL ORGANS; GLUCOSE; IRON OXIDES; MEDICINE; METABOLISM; MULTIVARIANT ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SUPERPARAMAGNETISM; SURFACE CHEMISTRY; TISSUE;

PRINCIPAL COMPONENT ANALYSIS;

AMINO ACID; GLUCOSE; LIPID; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; BIOMICS; BIOTRANSFORMATION; CHEMICAL COMPOSITION; CHEMISTRY; CONTROLLED STUDY; CROSS COUPLING REACTION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSPORT; ENERGY; GLUCOSE METABOLISM; KIDNEY FUNCTION; KIDNEY PARENCHYMA; LIPID METABOLISM; LIVER; LIVER FUNCTION; MALE; METABOLIC PARAMETERS; METABONOMICS; MOLECULE; NONHUMAN; PARTICLE SIZE; PLASMA; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SECRETION; SINGLE DRUG DOSE; SPLEEN; SPLEEN FUNCTION; SURFACE CHEMISTRY; TISSUE SPECIFICITY; URINE;

ANIMALS; BODY WEIGHT; DEXTRANS; DISCRIMINANT ANALYSIS; HUMANS; KIDNEY; LEAST-SQUARES ANALYSIS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MAGNETITE NANOPARTICLES; MALE; METABOLOMICS; ORGAN SPECIFICITY; PRINCIPAL COMPONENT ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; SPLEEN;

EID: 79960091200     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.05.035     Document Type: Article

References (43)

1. Bottero J.Y., Wiesner M.R. Considerations in evaluating the physicochemical properties and transformation of inorganic nanoparticles in water. Nanomedicine 2010, 5:1009-1014.
2. Aitken R.J., Chaudhry M.Q., Boxall A.B.A., Hull M. Manufacture and use of nanomaterials: current status in the UK and global trends. Occup Med 2006, 56:300-306.
3. Barcena C., Sra A.K., Gao J.M. Applications of magnetic nanoparticles in biomedicine. Nanoscale magnetic materials and applications 2009, 591-626. Springer, New York. J.P. Liu, E. Fullerton, O. Gutfleisch, D.J. Sellmyer (Eds.).
4. Metz S., Bonaterra G., Rudelius M., Settles M., Rummeny E.J., Dalerup-Link H.E. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur Radiol 2004, 14:1851-1858.
5. Gwinn M.R., Vallyathan V. Nanoparticles: health effects - pros and cons. Environ Health Perspect 2006, 114:1818-1825.
6. Kievit F.M., Veiseh O., Fang C., Bhattarai N., Lee D., Ellenbogen R.G., et al. Chlorotoxin labelled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano 2010, 8:4587-4594.
7. Hillyer J.F., Albrecht R.M. Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. J Pharm Sci 2001, 90:1927-1936.
8. Paolo B., Valerie G., Louise N., Marie-Elise P., Elisabete W., Jack S. Exposure to titanium dioxide and risk of lung cancer in a population-based study from Montereal. Scand J Work Environ Health 2001, 27:227-232.
9. Song Y., Li X., Du X. Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma. Eur Res J 2009, 34:559-567.
10. 1H nuclear magnetic resonance spectroscopy of liver tissues. Anal Biochem 2003, 323:26-32.
11. Griffin J.L., Walker L.A., Troke J., Osborn D., Shore R.F., Nicholson J.K. The initial pathogenesis of cadmium induced renal toxicity. FEBS Lett 2000, 478:147-150.
12. 1H MAS NMR spectroscopy. J Proteome Res 2009, 8:1423-1430.
13. Oghabian M.A., Gharehaghaji N., Amirmohseni S., Khoei S., Guiti M. Detection sensitivity of lymph nodes of various sizes using USPIO nanoparticles in magnetic resonance imaging. Nanomedicine 2010, 6:496-499.
14. Azoulay R., Olivier P., Baud O., Verney C., Santus R., Robert P., et al. USPIO (Ferumoxtran-10)-enhanced MRI to visualize reticuloendothelial system cells in neonatal rats: feasibility and biodistribution study. J Magn Reson Imaging 2008, 28:1046-1052.
15. Anzai Y., Piccoli C.W., Outwater E.K., Stanford W., Bluemke D.A., Nurenberg P., et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 2003, 228:777-788.
16. Feng J., Liu H., Zhang L., Bhakoo K., Lu L. An insight into the metabolic responses of ultra-small superparamagnetic particles of iron oxide using metabonomics analysis of biofluids. Nanotechnology 2010, 21:395101.
17. Veiseh O., Conroy S., Gunn J., Kohler N., Gabikian P., Lee D., et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 2005, 5:1003-1008.
18. Josephson L., Tung C.H., Moore A., Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-tat peptide conjugates. Bioconjug Chem 1999, 10:186-191.
19. Trygg J., Holmes E., Lundstedt T. Chemometrics in metabonomics. J Proteome Res 2007, 6:469-479.
20. Martin F-P J., Wang Y., Sprenger N., Yap I.K.S., Lundstedt T., Lek P., et al. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol 2008, 4:157.
21. Eriksson L., Toft M., Johansson E., Wold S., Trygg J. Separating Y-predictive and Y-orthogonal variation in multi-block spectra data. J Chemometrics 2006, 20:352-361.
22. Martin F.-P.J., Wang Y., Sprenger N., Yap I.K.S., Rezzi S., Ramadan Z., et al. Top-down systems biology integration of conditional prebiotic modulated transgenomic interactions in a humanized microbiome mouse model. Mol Syst Biol 2008, 4:205.
23. 1H NMR spectroscopy. Anal Chem 2005, 77:5570-5578.
24. Bollard M.E., Contel N.R., Ebbels T.M.D., Smith L., Beckonert O., Cantor G.H., et al. NMR-based metabolic profiling identifies biomarkers of liver regeneration following partial hepatoctomy in the rat. J Proteome Res 2010, 9:59-69.
25. Claus S.P., Tsang T.M., Wang Y., Cloarec O., Skordi E., Martin F.P., et al. Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol 2008, 4:219.
26. Yancey P.H. Organic osmolytes as compatible, metabolic and counteracting cytoprotectants in high osmolarity and other stresses. J Exp Biol 2005, 208:2819-2830.
27. Nakanishi T., Takamitsu Y., Sugita M. Role of taurine in the kidney: osmoregulatory taurine accumulation in renal medulla. Adv Exp Med Biol 1994, 359:139-148.
28. Lei R., Wu C., Yang B., Ma H., Shi C., Wang Q., et al. Integrated metabolomic analysis of the nano-sized copper particle-induced hepatotoxicity and nephrotoxicity in rats: a rapid in vivo screening method for nanotoxicity. Toxicol Appl Pharmacol 2008, 232:292-301.
29. Cho S.G., Kim M.Y., Kim H.J., Kim Y.S., Choi W., Shin S.H., et al. Chronic hepatitis: in vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings. Radiology 2001, 221:740-746.
30. Wu J., Xu W., Ming Z., Dong H., Tang H., Wang Y. Metabolic changes reveal the development of schistosomiasis in mice. PLoS Negl Trop Dis 2010, 4:e807.
31. Huang Z., Maness P.-C., Blake D.M., Wolfrum E.J., Smonlinski S.L., Jacoby W.A. Bactericidal mode of titanium dioxide photocatalysis. J Photochem Photobiol A 2000, 130:163-170.
32. 2 photocatalysis involves adsorption onto catalyst and the loss of membrane integrity. FEMS Microgiol Lett 2006, 258:18-24.
33. Gupta A.K., Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26:3995-4021.
34. Gupta A.K., Gupta M. Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials 2005, 26:1565-1573.
35. Boyer C., Whittaker M.R., Bulmus V., Liu J., Davis T.P. The design and utility of polymer-stabilized iron oxide nanoparticles for nanomedicine applications. NPG Asia Mater 2010, 2:23-30.
36. Bulte J.W.M., Ma L.D., Magin R.L., Kamman R.L., Hulstraert C.E., Go K.G., et al. Selective MR imaging of labeled human peripheral blood mononuclear cells by liposomes mediated incorporation of dextran-magnetic particles. Magn Reson Med 1993, 29:32-37.
37. Dias A.M.G.C., Hussain A., Marcos A.S., Roque A.C.A. A biotechnological perspective on the application of iron oxide magnetic colloids modified with polysaccharides. Biotechnol Adv 2011, 29:142-155.
38. Laurent S., Forge D., Port M., Roch A., Robic C., Vander Elst L., et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 2008, 108:2064-2110.
39. Booth R.G. Diet in the treatment of impaired kidney function (" nephritis" ) in dogs. J Small Anim Pract 1963, 4:355-358.
40. Spillane M., Schoch R., Cooke M., Harvey T., Greenwood M., Kreider R., et al. The effects of creatine ethyl ester supplementation combined with heavy resistance training on body composition, muscle performance, and serum and muscle creatine levels. J Int Soc Sports Nutr 2009, 6:6.
41. Pouliquen D., Le Jeune J.J., Perdrisot R., Ermias A., Jallet P. Iron oxide nanoparticles fro use as an MRI contrast agent: pharmacokinetics and metabolism. Magn Reson Imaging 1991, 9:275-280.
42. Briley-Saebo K., Bjørnerud A., Grant D., Ahlstrom H., Berg T., Kindberg G.M. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell Tissue Res 2004, 316:315-323.
43. Oken E., Pouliquen D., Okon P., Kovaleva Z.V., Stepanova T.P., Lavit S.G., et al. Biodegradation of magnetic dextran nanoparticles in the rat. A histologic and biophysical study. Lab Invest 1994, 71:895-903.